Refine by
Clinical Oncology Articles & Analysis
166 news found
Food and Drug Administration (FDA), further reinforcing the platform’s safety, reliability, and clinical value in modern radiation oncology. According to the official SFDA authorization document, RTsafe is authorized to market its patient-specific pre-radiotherapeutic end-to-end verification devices in the Kingdom enabling comprehensive end-to-end ...
ByRTsafe
Tempus is now offering these two IHC tests, which are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician’s discretion. ...
ByTempus
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be ...
ByBayer AG
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ...
ByBayer AG
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
The strategic transaction also adds significant tailwinds behind Inspirata’s ongoing focus to become the leading provider of cloud-based, enterprise software as a service (SaaS) solutions for Oncology Informatics – its main strategic pillar of growth. Critical workflows in Oncology Informatics, such as clinical trial matching and ...
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. ...
ByBayer AG
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered ...
The combination of existing IP and expertise in areas such as genomic data management, variant interpretation, NGS data quality control, and precision oncology, was fundamental to the partnership being awarded the contract. Kurt Zatloukal, Professor of Pathology at the Medical University Graz, said, “Phase one of this important project to deliver innovative NGS workflows, ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. ...
Initial results of the TORCH-2 study were presented at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting. About the TORCH Trial The TORCH trial was designed as a multi-regional clinical trial to evaluate the pharmacokinetics, safety, tolerability and efficacy of oral ATG-008 in hepatitis B positive (HBV+) hepatocellular ...
In addition to their outstanding clinical research in oncology, Peter Mac through Cell Therapies Pty Ltd has substantial experience in manufacturing of cell therapies for cancer.” The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. ...
Technologies like our unique Translational Index™, which synthesizes the potential for clinical success of any drug candidate, enable smarter decisions about how to advance drug asset programs and ultimately improve the lives of patients in ...
CST on December 10, 2022. Dr. Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine. ...
Proceeds and cost-savings from the divestiture of the CDMO facility and reduction in operations will be invested in advancing the Company’s lead immuno-oncology assets towards the clinic, as well as the continued development of the RubrYc® Discovery Engine, the artificial intelligence (“AI”) platform used to create the majority of ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. ...
She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. ...
ByArdigen
To date, multiple XPOVIO® regimens have been added to the clinical guidelines of major oncology societies in the U.S., the EU, and APAC, including 5 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma added to the guidelines of the National Cancer Care Network (NCCN); 4 regimens for the treatment of myeloma and 1 regimen for the ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ...
Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. ...